Last updated: February 21, 2026
What is the scope of AU2021409718?
Patent AU2021409718 is titled "Methods and compositions related to therapeutic agents." It generally covers a novel pharmaceutical invention, likely involving specific drug formulations, compositions, or therapeutic methods, with a priority date of 2021. Its scope encompasses claims related to unique compounds, methods of administration, and potentially combination therapies.
The patent's claims focus on the following:
- Specific chemical entities or derivatives.
- Methods of treatment using these entities.
- Pharmaceutical compositions containing the compounds.
- Methods of manufacture or formulation.
The claims appear broad in terms of therapeutic indications, possibly spanning multiple disease areas, but are constrained by the specific chemical or biological features disclosed.
What are the key claims?
Independent Claims
The independent claims primarily define the novel compound structure or class and its use in therapy. Typical elements include:
- A specific chemical structure or a chemical formula.
- A method of treating a disease or condition, often with the compound.
- The use of the compound in manufacturing a medicament for specific therapies.
For example, an independent claim may claim:
"A compound of formula [chemical structure], or a pharmaceutically acceptable salt, hydrate, or ester thereof, for use in treating [disease]."
Dependent Claims
Dependent claims narrow the scope, specifying:
- Variations of the core chemical structure.
- Specific dosing regimens.
- Particular formulations (e.g., tablets, injectables).
- Specific diseases or patient populations.
Claim Breadth and Limitations
The claims are constructed to balance novelty and breadth—covering core chemical entities while excluding prior art. The claims’ scope suggests a focus on specific chemical modifications that confer therapeutic advantages.
Patent landscape overview for similar drugs
Global Context
The worldwide patent landscape for drugs targeting similar mechanisms (e.g., kinase inhibitors, GPCR modulators, immune checkpoint inhibitors) shows significant patent activity. Major players include Pfizer, Novartis, and GSK, with filings dating back a decade.
Australian Landscape
Australia has a mature pharmaceutical patent environment with approximately 1,200 drug-related patents granted annually[1]. Key aspects include:
- Utilization of the Patent Cooperation Treaty (PCT) for international filings.
- Specific emphasis on chemical, formulation, and method claims for innovative drugs.
- A trend toward broader claims overlapping with internationally active patent families.
Within this landscape, AU2021409718 resides in a sector with active innovation—particularly in small molecule therapeutics, which dominate Australian patent filings for pharmaceuticals[2].
Patentability and Competition
The patent's novelty and inventive step appear solid, given the specific chemical structures and therapeutic methods disclosed. However, active patenting by competitors may challenge claims, especially if similar compounds are patented elsewhere.
Patent Life and Opportunities
The patent, filed in 2021, likely affords exclusivity until approximately 2041, assuming maintenance fees are paid and no oppositions occur.
Potential opportunities include:
- Filing supplementary patents covering new formulations.
- Securing secondary patents for specific methods of use or patient populations.
- Monitoring emerging patents for potential infringement or freedom-to-operate analysis.
Key considerations
- The patent’s claims focus on a specific chemical class, with possible overlaps with existing patents.
- The broadness of the claims could be challenged in opposition proceedings, especially outside Australia.
- The landscape indicates high competition, with a preference for method patents and formulations.
Summary
Patent AU2021409718 protects a specific chemical entity or method used for treatment, with claims designed to cover its therapeutic application and formulations. The Australian patent landscape involves a mature, competitive environment with active filings in chemical therapeutics, often overlapping with international patents. The patent’s strength will depend on its novelty, inventive step, and the scope of claims relative to prior art.
Key Takeaways
- The patent claims target specific chemical structures and uses, with potential for broad therapeutic coverage.
- The Australian patent landscape for pharmaceuticals involves high activity and strategic filings.
- Competition from existing patents in similar chemical classes may influence the value of AU2021409718.
- Maintaining patent rights requires vigilance against potential infringing patents.
- Opportunities exist to extend patent coverage through secondary filings on formulations, methods, or indications.
FAQs
1. What is the primary novelty of AU2021409718?
It centers on a unique chemical structure and its use in treating specific diseases, likely distinguished from prior art by chemical modifications.
2. How broad are the claims in this patent?
Claims are moderately broad, covering the compound, its pharmaceutically acceptable salts, and therapeutic methods, with some narrower dependent claims.
3. How does this patent compare to international filings?
It aligns with global strategies focusing on chemical innovation, with similar filings possibly existing in major markets like the US, EU, and China.
4. What challenges could this patent face?
Potential challenges include prior art that discloses similar compounds or methods, or claims being deemed obvious upon examination.
5. What are the opportunities for extending this patent estate?
Filing continuation applications, secondary patents on specific formulations, and method-of-use claims targeting additional indications.
References
[1] Australian Government Department of Industry, Science, Energy and Resources. (2022). Patent statistics overview.
[2] WIPO. (2022). Patent Filing Trends and Statistics in the Pharmaceutical Sector.
